CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin

Pharmacogenomics

Volumn 14, Issue 2, 2013, Pages 137-149

  Elens, Laure ^a,b   Nieuweboer, Annemieke ^a   Clarke, Stephen J ^c   Charles, Kellie A ^c   De Graan, Anne Joy ^a   Haufroid, Vincent ^b   Mathijssen, Ron Hj ^a   Van Schaik, Ron Hn ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CYP3A; CYP3A phenotyping; CYP3A4*22; CYP3A5*3; erythromycin; midazolam; pharmacogenetics; rs35599367; SNPs

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ERYTHROMYCIN; GENOMIC DNA; MIDAZOLAM;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREATH ANALYSIS; CANCER PATIENT; CYP3A4 22 GENE; CYP3A5 3 GENE; DEMETHYLATION; DRUG BLOOD LEVEL; ERYTHROMYCIN BREATH TEST; FEMALE; GENE; GENE ACTIVITY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RECOMBINATION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRON; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; PHENOTYPE; PLASMA CONCENTRATION-TIME CURVE; PROTEIN FUNCTION; PROTEIN METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM;

BREATH TESTS; CYTOCHROME P-450 CYP3A; DNA; ERYTHROMYCIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTRONS; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84872523142     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.202     Document Type: Article

References (52)

1. Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab. 3(6), 561-597 (2002). (Pubitemid 35331660)
2. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54(10), 1271-1294 (2002). (Pubitemid 35284253)
3. Shimada T, Guengerich FP. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl Acad. Sci. USA 86(2), 462-465 (1989). (Pubitemid 19037765)
4. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5́-upstream regulatory region. Biochem. Biophys. Res. Commun. 259(1), 201-205 (1999). (Pubitemid 29264018)
5. Westlind-Johnsson A, Malmebo S, Johansson A et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos. 31(6), 755-761 (2003). (Pubitemid 36617664)
6. Chiou WL, Jeong HY, Wu TC, Ma C. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin. Pharmacol. Ther. 70(4), 305-310 (2001). (Pubitemid 33022470)
7. Mathijssen RH, Loos WJ, Verweij J. Determining the best dose for the individual patient. J. Clin. Oncol. 29(33), 4345-4346 (2011).
8. Ozdemir V, Kalow W, Tang BK et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10(5), 373-388 (2000). (Pubitemid 30433571)
9. Baker SD, van Schaik RH, Rivory LP et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin. Cancer Res. 10(24), 8341-8350 (2004). (Pubitemid 40053395)
10. Ball SE, Scatina J, Kao J et al. Population distribution and effects on drug metabolism of a genetic variant in the 5́ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66(3), 288-294 (1999). (Pubitemid 29451761)
11. Floyd MD, Gervasini G, Masica AL et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13(10), 595-606 (2003). (Pubitemid 37311146)
12. He P, Court MH, Greenblatt DJ, Von Moltke LL. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin. Pharmacol. Ther. 77(5), 373-387 (2005). (Pubitemid 40719266)
13. Kharasch ED, Walker A, Isoherranen N et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin. Pharmacol. Ther. 82(4), 410-426 (2007). (Pubitemid 47414348)
14. Lepper ER, Baker SD, Permenter M et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin. Cancer Res. 11(20), 7398-7404 (2005). (Pubitemid 41507700)
15. Miao J, Jin Y, Marunde RL et al. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J. 9(5), 319-326 (2009).
16. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1́- hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab. Dispos. 30(12), 1491-1496 (2002).
17. Tomalik-Scharte D, Doroshyenko O, Kirchheiner J et al. No role for the CYP3A53 polymorphism in intestinal and hepatic metabolism of midazolam. Eur. J. Clin. Pharmacol. 64(10), 1033-1035 (2008).
18. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A41B5́-promoter region polymorphism. Clin. Pharmacol. Ther. 68(1), 82-91 (2000). (Pubitemid 30609830)
19. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274-286 (2011).
20. Elens L, Becker ML, Haufroid V et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21(12), 861-866 (2011).
21. Elens L, Bouamar R, Hesselink DA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57(11), 1574-1583 (2011).
22. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4 22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet. Genomics 22(5), 373-380 (2012).
23. Elens L, van Schaik RH, Panin N et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12(10), 1383-1396 (2011).
24. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin. Pharmacokinet. 49(4), 207-221 (2010).
25. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin. Pharmacokinet. 49(3), 141-175 (2010).
26. Mathijssen RH, van Schaik RH. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment. Eur. J. Cancer 42(2), 141-148 (2006). (Pubitemid 43083482)
27. Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin. Pharmacol. Ther. 73(3), 153-158 (2003). (Pubitemid 36269666)
28. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10(3), 187-216 (2000). (Pubitemid 30242736)
29. Gorski JC, Hall SD, Jones DR, Vandenbranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47(9), 1643-1653 (1994). (Pubitemid 24167278)
30. He P, Court MH, Greenblatt DJ, von Moltke LL. Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab. Dispos. 34(7), 1198-1207 (2006).
31. Patki KC, von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of CYP3A4 and CYP3A5. Drug Metab. Dispos. 31(7), 938-944 (2003). (Pubitemid 36759065)
32. Rivory LP, Slaviero KA, Hoskins JM, Clarke SJ. The erythromycin breath test for the prediction of drug clearance. Clin. Pharmacokinet. 40(3), 151-158 (2001). (Pubitemid 32324447)
33. Rivory LP, Watkins PB. Erythromycin breath test. Clin. Pharmacol. Ther. 70(4), 395-399 (2001). (Pubitemid 33022481)
34. Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology 20(2), 309-316 (1994). (Pubitemid 24233354)
35. Lown KS, Thummel KE, Benedict PE et al. The erythromycin breath test predicts the clearance of midazolam. Clin. Pharmacol. Ther. 57(1), 16-24 (1995).
36. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin. Pharmacol. Ther. 52(5), 471-478 (1992).
37. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4(4), 171-184 (1994). (Pubitemid 24269821)
38. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin. Pharmacol. Ther. 48(2), 120-129 (1990). (Pubitemid 20263240)
39. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64(2), 133-143 (1998). (Pubitemid 28423848)
40. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36(1), 89-96 (1989). (Pubitemid 19191264)
41. Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br. J. Anaesth. 73(5), 658-661 (1994). (Pubitemid 24323498)
42. Wrighton SA, Brian WR, Sari MA et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38(2), 207-213 (1990). (Pubitemid 20255306)
43. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin. Cancer Res. 6(4), 1255-1258 (2000). (Pubitemid 30226205)
44. Rivory LP, Slaviero K, Seale JP et al. Optimizing the erythromycin breath test for use in cancer patients. Clin. Cancer Res. 6(9), 3480-3485 (2000).
45. van der Bol JM, Mathijssen RH, Creemers GJ et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin. Cancer Res. 16(2), 736-742 (2010).
46. Mathijssen RH, de Jong FA, van Schaik RH et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J. Natl Cancer Inst. 96(21), 1585-1592 (2004).
47. Chaobal HN, Kharasch ED. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin. Pharmacol. Ther. 78(5), 529-539 (2005).
48. Kim JS, Nafziger AN, Tsunoda SM et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J. Clin. Pharmacol. 42(4), 376-382 (2002). (Pubitemid 34259770)
49. Nguyen AN, Hoffman JT, Tsunoda SM, Jang IJ, Ma JD. Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation. Int. J. Clin. Pharmacol. Ther. 50(7), 468-475 (2012).
50. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin. Pharmacol. Ther. 75(6), 529-538 (2004). (Pubitemid 38746603)
51. Kurnik D, Wood AJ, Wilkinson GR. The erythromycin breath test reflects Pglycoprotein function independently of cytochrome P450 3A activity. Clin. Pharmacol. Ther. 80(3), 228-234 (2006). (Pubitemid 44301092)
52. Lan LB, Dalton JT, Schuetz EG. Mdr1 limits CYP3A metabolism in vivo. Mol. Pharmacol. 58(4), 863-869 (2000).